Next Article in Journal
Predictive Factors of Functioning Adrenal Incidentaloma: A 15-Year Retrospective Study
Next Article in Special Issue
Histopathological Analysis of the Effect of Photodynamic Action on Post-Chemotherapy Excised Breast Cancer Tissue
Previous Article in Journal
Life after Burn, Part I: Health-Related Quality of Life, Employment and Life Satisfaction
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 58
Issue 5
10.3390/medicina58050600
Review Report
medicina-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Commentary
Peer-Review Record

Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward

Medicina 2022, 58(5), 600; https://doi.org/10.3390/medicina58050600
by Alessandro Rizzo 1,*, Antonio Cusmai 1, Gennaro Gadaleta-Caldarola 2 and Gennaro Palmiotti 1
Reviewer 2: Anonymous
Medicina 2022, 58(5), 600; https://doi.org/10.3390/medicina58050600
Submission received: 2 April 2022 / Revised: 22 April 2022 / Accepted: 24 April 2022 / Published: 27 April 2022
(This article belongs to the Special Issue Recent Advances in Breast Cancer Diagnosis, Treatment, Psychology, Management, and Reconstruction)

Round 1

Reviewer 1 Report

The editorial is clear, comprehensive and relevant, although some inconsistencies of the introduction (parts about mTNBC) are to revise.

 

Line 26: please review name of LAG-3

Line 28-30: Please review given ORR, considering distinguishing between therapeutic lines and citing Keynote trials properly.

Line 32: Citation 9 refers to a review including combination therapy. Maybe NCT01375842 was intended to be cited instead? 

Line 34: I suggest specifying PD-L1 overexpression according to atezolizumab label (IC score).

Author Response

Dear Reviewer,

Thank you so much for the time spent revising our paper. 

We have modified all the parts you indicated, as suggested.

All our changes have been highlighted in blue color in the revised paper.

Thank you again

Reviewer 2 Report

In this commentary the authors summarize and give their personal perspective about the results of 3 chemo-immunotherapy trials in triple negative breast cancer neo-adjuvant/adjuvant setting.

The article is well written but should undergo some minor revision.

In order to consistently report the findings of the studies I would suggest to:

  • Provide the pCR rates in the experimental and control arm of the Keynote-522 trial;
  • Provide information about the adverse events registered in the Keynote522 and GeparNuevo trials.

Additionally, in the conclusive section (What the future will be like? Open questions) authors should comment about the role of chemo-immunotherapy regimens in triple negative BRCA mutated breast cancer patients, given the recent approval of olaparib in the adjuvant setting. A comment about the role of post-neoadjuvant capecitabine (CREATE-X trial) in current scenario should also be added.

Author Response

Dear Reviewer,

Thank you so much for your time spent revising our paper. 

We modified several parts of the manuscript, as suggested.

All our changes related to your comments have been reported in green color.

Thank you again.

Regards

Round 2

Reviewer 1 Report

Citation Nr. 8 still refers to a HNSCC-trial (KeyNote-048). 

Back to TopTop